Geneva, Switzerland

Preglem Sa

Calculating rank
USPTO Granted Patents = 7

% Expired Patents = 100.0



Forward Citations = 86

Loading Chart...
Loading Chart...

12 inventors (with patents filed for the assignee):

goldMedal Ernest Loumaye (6 out of 12 patents)

silverMedal Ian Osterloh (2 out of 89 patents)

bronzeMedal Elke Bestel (2 out of 2 patents)

4.  Valérie Boujac (1 out of 1 patent)

5.  Bestel Elke (1 out of 1 patent)

6.  Osterloh Ian (1 out of 1 patent)

7.  Loumaye Ernest (1 out of 1 patent)

8.  Dacquin Annie (1 out of 1 patent)

9.  Jean Florence (1 out of 1 patent)

10.  Bartholomeus C J M Fauser (1 out of 1 patent)

11.  Jean-Pierre Gotteland (1 out of 20 patents)

12.  Alain Gougeon (1 out of 1 patent)

13.  Ernest Loumaye (0 patent)

14.  Bartholomeus Cjm Fauser (0 patent)

15.  Valérie Cayron-Elizondo (0 patent)


7 patents:

Company Overview
Preglem Sa is a leading pharmaceutical company specializing in the development and commercialization of innovative treatments for rare and orphan diseases. With a strong focus on research and development, Preglem Sa aims to improve the lives of patients worldwide by providing effective and accessible therapies. Preglem Sa is dedicated to making a positive impact on the healthcare industry through cutting-edge medical solutions and a commitment to excellence.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

7 Patents

#51 in Geneva

#1,436 in Switzerland

Geneva, CH
Geneva, Switzerland
Forward Citations = 86

12 inventors:

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Preglem Sa. Retrieved from https://idiyas.com/company/preglem-sa

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…